Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.70 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424470 | 0.98 | EPHX1 (0.73) | EPHX1BCHEGAAALDH1A1KDM4E | |
| SCHEMBL20928290 | 0.96 | EPHX1 (0.65) | EPHX1BCHEGAAALDH1A1KDM4E | |
| SCHEMBL104271 | 0.92 | EPHX1 (0.58) | EPHX1BCHEGAAALDH1A1KDM4E | |
| SCHEMBL22134964 | 0.89 | EPHX1 (0.66) | EPHX1BCHEGAANAAA | |
| SCHEMBL22136179 | 0.87 | EPHX1 (0.69) | EPHX1BCHEGAANAAA | |
| SCHEMBL16374741 | 0.87 | EPHX1 (0.64) | EPHX1BCHEGAANAAA | |
| SCHEMBL2801495 | 0.87 | EPHX1 (0.69) | EPHX1BCHEGAANAAA | |
| SCHEMBL16690968 | 0.87 | EPHX1 (0.54) | EPHX1BCHEGAAALDH1A1KDM4E | |
| SCHEMBL14703637 | 0.86 | EPHX1 (0.62) | EPHX1GAANAAA | |
| SCHEMBL12991745 | 0.86 | EPHX1 (0.67) | EPHX1BCHEGAANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024056019-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BEIGENE, LTD. (KY) | 2024-03-21 | — | — | WO | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3802536-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | EPHX1 3845/4885BCHE 4458/4885GAA 3049/4885 |
| US-11773082-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | EPHX1 2859/4885BCHE 4606/4885GAA 2971/4885 |
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | EPHX1 2859/4885BCHE 4606/4885GAA 2971/4885 |
| US-20240294506-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | EPHX1 2859/4885BCHE 4606/4885GAA 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.